OncoImmunology
Volume 9, 2020 - Issue 1
Open access
5,590
Views
22
CrossRef citations to date
0
Altmetric
Back Matter
Identification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody
Dong Zhanga Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-1068-8334View further author information
Feng Jianga Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Rinat Zaynagetdinova Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Hui Huanga Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Vanita D. Soodb Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USA
https://orcid.org/0000-0001-6714-3725View further author information
Hong Wanga Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Xinyan Zhaob Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Molly H. Jenkinsa Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USA
https://orcid.org/0000-0001-5150-2818View further author information
Qingyong Jib Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Youbin Wangb Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, David P. Nannemannb Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Djordje Musilc Discovery and Development Technologies, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
, John Wesolowskib Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Andrea Paolettid Discovery and Development Technologies, Merck Healthcare KGaA, Colleretto Giacosa, ItalyView further author information
, Tin Bartholomewa Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Melissa G. Dernera Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Qi Anb Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
, Christel Ifflandb Discovery and Development Technologies, EMD Serono Research and Development Institute, Billerica, MA, USAView further author information
& Joern-Peter Hallea Department of Immuno-Oncology, EMD Serono Research and Development Institute, Billerica, MA, USA;e Department of Immuno-Oncology, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
show all
Article: 1744921
|
Received 01 Nov 2019, Accepted 25 Feb 2020, Published online: 01 Apr 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.